Email updates

Keep up to date with the latest news and content from BMC Dermatology and BioMed Central.

Open Access Research article

Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence

Kim A Papp*, Darryl Toth and Les Rosoph

BMC Dermatology 2006, 6:9  doi:10.1186/1471-5945-6-9

Article Metrics

6550
Total accesses

Article metric FAQ

Accesses  

  • Last 30 days: 25 accesses
  • Last 365 days: 314 accesses
  • All time: 6550 accesses

These numbers are accesses on BioMed Central websites only, and an underestimate of total usage. More information